Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

US Oncology Research Network Participates In Phase III Follow-up Study To BiPar's Investigational Cancer Drug BSI-201
US Oncology, Inc. today announced that US Oncology Research will participate in the BiPar Sciences" Phase III, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C), with or without BSI-201, in patients with Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2-negative metastatic breast cancer.
generic viagra online
Development Of DNA Drugs Gives Hope To Lupus Patients
A generation of DNA-like compounds, class R inhibitory oligonucleotides (INH-ODNs), have been shown to effectively inhibit cells responsible for the chronic autoimmune condition lupus. Researchers writing in BioMed Central"s open access journal Arthritis Research & Therapy have demonstrated the anti-inflammatory effects of the INH-ODNs in both in vitro and mouse experiments.
News of the day
Stinging Insects Can Cause Real Summer Fears But There Are Real Ways To Prevent Them
The term Cnidophobia may be uncommon but what it describes is not. Cnidophobia is the fear of insect stings. Although a "phobia" may seem to be an overreaction to what some consider nuisance pests, homeowners must recognize the health threats associated with stinging insects. The National Pest Management Association (NPMA) reports more than half million people are sent to the emergency room every year due to stinging insects, which is why these summer pests must be addressed efficiently and effectively.
Sexual Health

First-Line Nab-Paclitaxel Is Superior To Docetaxel For Metastatic Breast Cancer

CHICAGO, May 26, 2009 - New data show that nab-paclitaxel (AbraxaneR for Injectable Suspension) prolongs investigator-assessed, median progression-free survival (PFS) by almost seven months versus the highest standard dose of docetaxel in women with metastatic breast cancer. Nab-paclitaxel is a novel albumin-bound paclitaxel, an established chemotherapy agent, combined with albumin, a very small naturally-occurring protein. The findings, from a phase 2 trial that enrolled 302 women with previously untreated metastatic breast cancer, were published online today in the Journal of Clinical Oncology (JCO). "We believe that the results suggest that weekly nab-paclitaxel may be a suitable alternative to the taxane docetaxel given every three weeks for the first-line treatment of metastastic breast cancer," principal investigator William J. Gradishar, MD, Director of Breast Medical Oncology at Northwestern University"s Robert H. Lurie Comprehensive Cancer Center, said. In prior research involving metastatic breast cancer patients, nab-paclitaxel had produced significantly higher anti-tumor activity than solvent-based paclitaxel. The present study was undertaken to evaluate the efficacy and safety of three nab-paclitaxel dosing regimens (weekly versus every three weeks) and to examine differences in safety and efficacy between these dosing regimens of nab-paclitaxel and docetaxel administered at the highest standard dose. Patients were randomized to receive nab-paclitaxel 300 mg/m2 every three weeks (q3w), 100 mg/m2 weekly, 150 mg/m2 weekly, or docetaxel 100 mg/m2 q3w. Results showed that patients treated with nab-paclitaxel 150 mg/m2 weekly had a significantly longer median PFS than docetaxel-treated patients when assessed by both the independent radiologists (12.9 versus 7.5 months, respectively, p=0.0065) and the investigator (14.6 months versus 7.8 months, respectively, p=0.012) using RECIST guidelines. The overall response rate (ORR) tended to be higher with both weekly nab-paclitaxel regimens than docetaxel by independent radiology review. The investigator assessment found that the difference in ORR between both weekly nab- paclitaxel doses and docetaxel was statistically significant. Review by both the investigator and the independent radiologist found a significantly higher disease control rate (DCR) in patients receiving either dose of weekly nab-paclitaxel compared to docetaxel. All nab-paclitaxel doses showed an overall superior safety and toxicity profile over docetaxel. Dr. Gradishar said that the results of this study bolster earlier data identifying a role for nab-paclitaxel as a suitable option to docetaxel for first-line treatment of metastatic breast cancer. The study was sponsored by Abraxis BioScience, Inc. in Los Angeles, California. Written by Jill Stein Jill Stein is a Paris-based freelance medical writer. jillstein03(at)gmail.com Copyright: Medical News Today Not to be reproduced without permission of Medical News Today


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009